Home > Insider Trading > Lisata Therapeutics Inc. > Profile

Lisata Therapeutics Inc. (LSTA)

Market is closed

Sector: Pharmaceutical Preparations

Related Insiders

K Kristen Buck, Evp, R&D And Cmo, 2024-10-02
James Nisco, Svp, Fin/Treas, Chief Actg Off, 2024-10-02
J David Mazzo, President & Ceo, 2024-10-02

K Kristen Buck, Evp, R&D And Cmo, 2024-10-02
James Nisco, Svp, Fin/Treas, Chief Actg Off, 2024-10-02
J David Mazzo, President & Ceo, 2024-10-02
M Steven Klosk, Director, 2024-01-11
Heidi Henson, Director, 2024-01-11
Louise Cynthia Flowers, Director, 2024-01-11
B Gregory Brown, Director, 2024-01-11
Mohammad Azab, Director, 2024-01-11
Erkki Ruoslahti, Director, 2023-01-11
W. David Slack, President & Cbo, 2023-01-11
C Todd Girolamo, Clo, Svp Of Corp Dev, 2022-01-18
Clem Anne Whitaker, Director, 2022-01-12
G Peter Traber, Director, 2022-01-12
S Steven Myers, Director, 2022-01-12
H. Michael Davidson, Director, 2022-01-12
Joseph Talamo, Svp And Cfo, 2020-01-15
W Douglas Losordo, See Remarks, 2020-01-15
A Robert Preti, Other, 2017-05-22
Health Sanford, Large Shareholder, 2017-03-23
Sanford, Large Shareholder, 2017-03-23
Eric Wei, Director, 2017-02-08
J Richard Berman, Director, 2017-01-31
Ltd. Construction Newhall, Large Shareholder, 2016-09-26
L Andrew Pecora, Director, 2016-06-23
S Robert Vaters, President & Cfo, 2015-08-13
L Robin Smith, Executive Chair Of The Board, 2015-06-05
D Martyn Greenacre, Director, 2015-06-05
Drew Bernstein, Director, 2015-06-05
M Catherine Vaczy, General Counsel, 2015-04-15
Iv Robert Dickey, Chief Financial Officer, 2015-01-03
W Stephen Potter, Executive Vice President, 2015-01-03
Rimasia Capital Partners Manager, Ltd., Large Shareholder, Director, 2015-01-03
Rimasia Capital Partners, L.p., Large Shareholder, Director, 2015-01-03
Rimasia Capital Partners Gp, Ltd., Large Shareholder, Director, 2015-01-03
Rimasia Capital Partners Gp, L.p., Large Shareholder, Director, 2015-01-03
Robert Dillman, See Remarks, 2014-05-10
Hans Keirstead, See Remarks, 2014-05-10
Alan Larry May, Chief Financial Officer, 2013-01-05
Edward Geehr, Director, 2012-07-03
E Martin Schmieg, Vice President - Corporate Dev, 2012-06-28
Jonathan Sackner-Bernstein, Vp Clinical Dev & Reg Affairs, 2012-04-04
Mingsheng Shi, See Remarks, 2012-01-07
Jason Kolbert, See Remarks, 2012-01-07
Ian Zhang, See Remarks, 2011-04-07
G Alan Harris, See Remarks, 2011-04-07
Anthony Salerno, See Remarks, 2010-06-11
M Jian Zhang, See Remarks, 2010-06-11
Ltd Finance Fullbright, Large Shareholder, 2010-04-28
Ltd Holdings Biomedical Enhance, Large Shareholder, 2010-03-30
Southpoint Capital Advisors Lp Southpoint Gp, Lp Southpoint, Large Shareholder, 2009-06-22

Show All Insiders (50)

Hedge Fund Popularity

Display

Display Share Price

Display Large Version

Hedge Fund Holdings

Filing Period:

No.	Hedge Fund	Shares	Value	Activity	% Port
1.	Renaissance Technologies Jim Simons	103,622	$310,866	+2%	0%

Insider Trading: Purchases See All

Insider	Price	Amount	Relationship	Remaining Holdings	Date	Form 4
Myers	$0.89	33,785	Director	146,839	2021-12-08	Filing
Davidson	$1.80	55,525	Director	106,588	2020-09-09	Filing
Mazzo	$1.40	20,000	Officer, Director	259,543	2015-08-17	Filing
Vaters	$1.35	12,385	Officer, Director	228,750	2015-08-12	Filing
Vaters	$1.24	81,000	Officer, Director	216,365	2015-08-11	Filing

Insider Trading: Sales See All

Insider	Price	Amount	Relationship	Remaining Holdings	Date	Form 4
Wei	$4.77	6,575	Director	172,223	2017-02-07	Filing
Wei	$4.75	500	Director	178,798	2017-02-06	Filing
Wei	$4.76	1,525	Director	179,298	2017-02-03	Filing
Wei	$4.75	1,400	Director	180,823	2017-02-02	Filing
Wei	$4.51	5,000	Director	182,223	2017-02-02	Filing

Institutional Investors' Holdings

Filing Period:

No.	Name	Shares	Value	% Port
1.	Bml Capital Management, Llc	269,839	$736,660	0.55%
2.	Vanguard Group Inc	176,965	$483,114	0%
3.	Blackrock Inc.	56,250	$153,563	0%
4.	Geode Capital Management, Llc	43,390	$118,486	0%
5.	Susquehanna International Group, Llp	33,749	$92,135	0%